Categorization of COVID-19 severity to determine mortality risk

被引:15
作者
Garry, Elizabeth M. [1 ]
Weckstein, Andrew R. [1 ]
Quinto, Kenneth [2 ]
Bradley, Marie C. [3 ]
Lasky, Tamar [4 ]
Chakravarty, Aloka [4 ]
Leonard, Sandy [5 ]
Vititoe, Sarah E. [1 ]
Easthausen, Imaani J. [1 ]
Rassen, Jeremy A. [1 ]
Gatto, Nicolle M. [1 ]
机构
[1] Aetion Inc, New York, NY 10001 USA
[2] US FDA, Off Med Policy, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[3] US FDA, Div Epidemiol, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[4] US FDA, Off Commissioner, Silver Spring, MD USA
[5] HealthVerity, Partnerships & RWD, Philadelphia, PA USA
关键词
administrative claims; healthcare; COVID-19; severity of illness index;
D O I
10.1002/pds.5436
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Algorithms for classification of inpatient COVID-19 severity are necessary for confounding control in studies using real-world data. Methods Using Healthverity chargemaster and claims data, we selected patients hospitalized with COVID-19 between April 2020 and February 2021, and classified them by severity at admission using an algorithm we developed based on respiratory support requirements (supplemental oxygen or non-invasive ventilation, O2/NIV, invasive mechanical ventilation, IMV, or NEITHER). To evaluate the utility of the algorithm, patients were followed from admission until death, discharge, or a 28-day maximum to report mortality risks and rates overall and by stratified by severity. Trends for heterogeneity in mortality risk and rate across severity classifications were evaluated using Cochran-Armitage and Logrank trend tests, respectively. Results Among 118 117 patients, the algorithm categorized patients in increasing severity as NEITHER (36.7%), O2/NIV (54.3%), and IMV (9.0%). Associated mortality risk (and 95% CI) was 11.8% (11.6-12.0%) overall and increased with severity [3.4% (3.2-3.5%), 11.5% (11.3-11.8%), 47.3% (46.3-48.2%); p < 0.001]. Mortality rate per 1000 person-days (and 95% CI) was 15.1 (14.9-15.4) overall and increased with severity [5.7 (5.4-6.0), 14.5 (14.2-14.9), 32.7 (31.8-33.6); p < 0.001]. Conclusion As expected, we observed a positive association between the algorithm-defined severity on admission and 28-day mortality risk and rate. Although performance remains to be validated, this provides some assurance that this algorithm may be used for confounding control or stratification in treatment effect studies.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 23 条
[1]  
[Anonymous], NY TIMES NYT
[2]  
Barrett CE, 2022, MMWR-MORBID MORTAL W, V71, P59, DOI 10.15585/mmwr.mm7102e2
[3]  
Burn E., 2021, PREPRINT, DOI [10.1101/2020.11.25.20229088, DOI 10.1101/2020.11.25.20229088]
[4]  
Centers for Disease Control National Center for Health Statistics (CDCNCHS), IN HOSP MORT HOSP CO
[5]   A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System [J].
Cocoros, Noelle M. ;
Fuller, Candace C. ;
Adimadhyam, Sruthi ;
Ball, Robert ;
Brown, Jeffrey S. ;
Dal Pan, Gerald J. ;
Kluberg, Sheryl A. ;
Lo Re, Vincent, III ;
Maro, Judith C. ;
Nguyen, Michael ;
Orr, Robert ;
Paraoan, Dianne ;
Perlin, Jonathan ;
Poland, Russell E. ;
Driscoll, Meighan Rogers ;
Sands, Kenneth ;
Toh, Sengwee ;
Yih, W. Katherine ;
Platt, Richard .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (07) :827-837
[6]  
Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI [10.1128/CMR.00028-20, 10.1038/s41432-020-0088-4]
[7]   Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2 [J].
Di Fusco, Manuela ;
Moran, Mary M. ;
Cane, Alejandro ;
Curcio, Daniel ;
Khan, Farid ;
Malhotra, Deepa ;
Surinach, Andy ;
Miles, Amanda ;
Swerdlow, David ;
McLaughlin, John M. ;
Nguyen, Jennifer L. .
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :1248-1260
[8]  
Food and Drug Administration (FDA), FRAM FDAS REAL WORLD
[9]  
Food and Drug Administration (FDA), COVID 19 DEV DRUGS B
[10]   A combined comorbidity score predicted mortality in elderly patients better than existing scores [J].
Gagne, Joshua J. ;
Glynn, Robert J. ;
Avorn, Jerry ;
Levin, Raisa ;
Schneeweiss, Sebastian .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (07) :749-759